Condition: Ischemic Stroke · Transient Ischemic Attack · Sponsor: VASCage GmbH
Stroke is the second leading cause of death and one of the main contributors to disability. Patients who survive the acute phase of ischemic stroke and those with transient ischemic attack (TIA) are at high risk of subsequent vascular events. Importantly, recurrent strokes are associated with a higher social and economic impact, higher case fatality, and worse clinical outcome than first-ever strokes. The burden of post-stroke complications, residual deficits, and inadequate medical and psychosocial care all contribute to long-term disability and reduced quality of life in these patients. The Department of Neurology of the Medical University Innsbruck undertook the STROKE-CARD trial (NCT02156778) between 2014 and 2018 with follow-up until 2019 to evaluate the efficacy of the Post-Stroke disease-management program STROKE-CARD care. After implementation of STROKE-CARD care, the investigators aim to document the quality of post-stroke care and compare outcome parameters to historical cohorts and the change over time. Furthermore the investigators aim to gain a large data-resource for future research of biomarkers, disease mechanisms, prognosis and imaging mechanisms for R\&D.
This description comes directly from the study's public registry record.
Christian Böhme, MD · +43 512 504 · christian.boehme@i-med.ac.at
Ulrike Pachmann, MSc · +43 512 554435 · ulrike.pachmann@vascage.at
Always discuss trial participation with your own doctor first.
| Hospital St. John of God | Vienna, State of Vienna, Austria | Recruiting |
| Medical University Innsbruck | Innsbruck, Tyrol, Austria | Recruiting |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.